Anargyros Skaliotis, PA
Surgical · North Dartmouth, MANPI 1265491807
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 331 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AstraZeneca accounts for 65.0% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $1,929 and has fallen 55.5% since, to $858 in 2025. Among surgical clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 331 payments — averaging $21.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Electromed, Inc.$379
- GSK$363
- Mylan Specialty L.p.$313
- E.r. Squibb & Sons, L.L.C.$262
- Sanofi$196
- plus $966 from 19 others
What the payments were for
- Food & beverage$7,076100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 203 | $4,597 |
| Electromed, Inc. | 24 | $379 |
| GSK | 20 | $363 |
| Mylan Specialty L.p. | 16 | $313 |
| E.r. Squibb & Sons, L.L.C. | 13 | $262 |
| Sanofi | 10 | $196 |
| Boehringer Ingelheim | 7 | $171 |
| United Therapeutics Corporation | 7 | $161 |
| Axsome Therapeutics, Inc. | 5 | $113 |
| Genentech USA, Inc. | 4 | $55 |
| Amgen | 3 | $46 |
| Regeneron Healthcare Solutions, Inc. | 2 | $43 |
| Baxter Healthcare | 2 | $42 |
| Pfizer | 2 | $42 |
| Viatris Specialty LLC | 2 | $40 |
| Philips North America LLC | 2 | $37 |
| Grifols USA, LLC | 1 | $35 |
| Verona Pharma, Inc. | 1 | $31 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Insmed, Inc. | 1 | $27 |
| Harmony Biosciences LLC | 1 | $25 |
| Novartis | 1 | $20 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $19 |
| 3b Medical, Inc. | 1 | $18 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$755
- FASENRA$755
- TEZSPIRE$505
- TUDORZA PRESSAIR$314
- SYMBICORT$191
How this compares
$7,076 in reported general payments places this provider in the 95th percentile of 312 surgical providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 431 | $336,086 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 273 | $195,320 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 214 | $122,882 |
| Spiriva RespimatTiotropium Bromide | 135 | $108,661 |
| Fasenra PenBenralizumab | 19 | $106,401 |
| Breo ElliptaFluticasone/Vilanterol | 189 | $97,173 |
| Dupixent PenDupilumab | 26 | $91,616 |
| TezspireTezepelumab-Ekko | 19 | $77,758 |
| Incruse ElliptaUmeclidinium Bromide | 177 | $74,052 |
| NucalaMepolizumab | 19 | $70,110 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 102 | $53,498 |
| XolairOmalizumab | 25 | $48,382 |
| SymbicortBudesonide/Formoterol Fumarate | 145 | $46,710 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 81 | $36,935 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 54 | $31,855 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Nucala, Anoro Ellipta | $363 | $646,884967 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere | $4,597 | $356,723518 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $171 | $263,398403 claims |
| MerckDulera, Belsomra | $16 | $29,60370 claims |
| PfizerEliquis | $42 | $24,06038 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 312 surgical providers in Massachusetts.
Other surgical in North Dartmouth
- Gregory DeconciliisWaltham$27K
- Lampros MinosWaltham$18K
- Nicolas DesjardinsSomerville$10K
- Robert KenneyChestnut Hill$8K
- Michael LlewellynBoston$8K
- Caily IrwinCambridge$6K
- Courtney FioreDanvers$6K
- Dana GoldenseBoston$5K
- Stephanie PenaNatick$5K
- Jarett LandmanPeabody$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.